Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04472429 · ClinicalTrials.gov registry record · Phase 3
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
A Phase 3 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 308
- Enrollment target
NCT04472429 is a Phase 3 study that has completed, run by Incyte Corporation. The registered enrollment target is 308 participants.
The verdict
NCT04472429, a Phase 3 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 308 participants
- Enrollment target
Study Summary
This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- DRUG retifanlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2021-01-12 |
| Est. Completion | 2025-09-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04472429
The ClinicalTrials.gov registry entry for NCT04472429 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT04472429 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04472429 about?
NCT04472429 is a clinical study titled "Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).". This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.
What is the current status of trial NCT04472429?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 308 participants. The study started on 2021-01-12. Estimated completion is 2025-09-26.
What interventions are being tested in trial NCT04472429?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), retifanlimab (DRUG).
Who is sponsoring clinical trial NCT04472429?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.